Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


Maring

Clarence J. Maring, Palatine, IL US

Patent application numberDescriptionPublished
20080214528ANTI-INFECTIVE AGENTS - The present invention provides HCV polymerase inhibiting compounds having the formula (I):09-04-2008
20090176784ANTI-INFECTIVE AGENTS AND USES THEREOF - This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.07-09-2009
20090186912ANTI-INFECTIVE AGENTS AND USES THEREOF - This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.07-23-2009
20100120753Anti-Infective Agents - The present invention provides HCV polymerase inhibiting compounds having the formula (I):05-13-2010
20100317568Anti-Viral Compounds - Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.12-16-2010
20110070193Anti-Infective Agents and Uses Thereof - This invention relates to: (a) compounds and salts thereof that, inter alia, inhibit HCV; (b) intermediates useful for the preparation of such compounds and salts; (c) compositions comprising such compounds and salts; (d) methods for preparing such intermediates, compounds, salts, and compositions; (e) methods of use of such compounds, salts, and compositions; and (f) kits comprising such compounds, salts, and compositions.03-24-2011
20110092415Anti-Viral Compounds - Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.04-21-2011
20110160233ANTI-VIRAL COMPOUNDS - Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, co-formulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections.06-30-2011
20110207699Anti-Viral Compounds - Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection.08-25-2011

Patent applications by Clarence J. Maring, Palatine, IL US

Daniel Maring, Reichstett FR

Patent application numberDescriptionPublished
20100082497Providing Foundation Application as Enterprise Services - Methods and apparatus, including systems and computer program products, for a services architecture design that provides enterprise services having foundation layer functionality at the level of an enterprise application. The design includes a set of service operations, process components, and optionally deployment units. Suitable business objects are also described.04-01-2010

Kathrin Maring, Bonn DE

Patent application numberDescriptionPublished
20110319415Susceptibility to HSP90-Inhibitors - The present invention relates to a method of selecting (a) cell(s), (a) tissue(s) or (a) cell culture(s) with susceptibility to an HSP90 inhibitor. Also a method for determining the responsiveness of a mammalian tumor cell or cancer cell to treatment with an HSP90 inhibitor is described herein. In particular, the present invention provides for an in vitro method for the identification of a responder for or a patient sensitive to an HSP90 inhibitor and uses of an oligo- or polynucleotide capable of detecting (an) activating mutation(s) in the KRAS gene are provided. The present invention also relates to a method of monitoring the efficacy of a treatment of a cancer characterized by the presence of at least one activating mutation in the KRAS gene, and. optionally, in the EGFR gene and/or the BRAF gene. In addition, a method of predicting the efficacy of a cancer treatment is described, in particular in a cancer that is characterized by the presence of at least one activating mutation in the KRAS gene. and. optionally, in the EGFR gene and/or the BRAF gene. Also the use of a (transgenic) non-human animal or a (transgenic) cell having at least one activating mutation in the KRAS gene, and, optionally, in the EGFR gene and/or the BRAF gene for screening and/or validation of a medicament for the treatment of said cancer is described and a kit useful for carrying out the methods described herein is provided.12-29-2011

Wolfram Maring, Hamburg DE

Patent application numberDescriptionPublished
20100316192EMITTER FOR X-RAY TUBES AND HEATING METHOD THEREFORE - It is described an emitter (12-16-2010

Wolfram Maring, Eindhoven DE

Patent application numberDescriptionPublished
20100020937ELECTRON OPTICAL APPARATUS, X-RAY EMITTING DEVICE AND METHOD OF PRODUCING AN ELECTRON BEAM - It is described an electron optical arrangement, a X-ray emitting device and a method of creating an electron beam. An electron optical apparatus (01-28-2010